AGIO vs IRON: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AGIO and IRON share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AGIO and IRON exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia. The company is pursuing accelerated approval of mitapivat in sickle cell disease and, as of July 2026, the FDA granted Priority Review to that application. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib).

Full AGIO guide

Disc Medicine (Nasdaq: IRON) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel treatments for serious hematologic diseases. Its programs aim to modify the biological pathways behind red blood cell formation and function, principally heme biosynthesis and iron homeostasis. The lead pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), DISC-0974 (an anti-hemojuvelin antibody) for anemia of myelofibrosis, and DISC-3405 (an anti-TMPRSS6 antibody) being studied in conditions like polycythemia vera and sickle cell disease. The current company was formed when Disc Medicine reverse-merged into Gemini Therapeutics in December 2022 and began trading under the ticker IRON.

Full IRON guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AGIO drivers: Mitapivat franchise expansion; Sickle cell Priority Review.
• IRON drivers: Bitopertin and the APOLLO Phase 3 catalyst; DISC-0974 in anemia of myelofibrosis.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Agios remains deeply unprofitable, reporting quarterly GAAP losses well above a dollar per share while product revenue is still modest. For IRON, disc Medicine is a clinical-stage company with essentially no product revenue, so it is not profitable and its value rests on trials that can fail.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AGIO if you believe its drivers more; IRON if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AGIO and IRON guides.

AGIO. Agios trades at a large multiple of its small product revenue, reflecting a valuation driven by pipeline potential rather than current earnings. The company is unprofitable, with R&D (~$81M) and SG&A (~$48M) in Q1 2026 far exceeding revenue. The roughly $1 billion cash balance represents a large share of the market capitalization, which cushions financing risk but also signals that the market is paying primarily for future indications like sickle cell disease.

IRON. As a clinical-stage biotech, Disc has no meaningful product sales, so traditional metrics like P/E do not apply and the company is valued on its pipeline's expected value and its cash. Its roughly $791 million cash pile is large relative to its market cap, meaning a big share of the value is the balance sheet plus the option value of its programs. The market cap and share price can swing sharply around trial data and FDA decisions.

Headline figures (approximate, JUNE 2026): AGIO shows revenue (ttm) ~$66M, fy2025 revenue ~$54M, q1 2026 revenue ~$20.7M (up ~138% YoY), q1 2026 gaap eps ~-$1.69; IRON shows revenue (ttm) ~$0 (pre-revenue, clinical stage), net loss (approx, ttm) ~$180 million, cash and investments ~$791 million, net cash position ~$760 million (~$20/share).

AGIO and IRON are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AGIO and IRON exposure against your real portfolio. It is not an investment adviser.